Worldwide Clinical Trials has announced its Early Phase Clinical Pharmacology Unit (CPU) has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, the clinic passed an evaluation process that involved an in-depth inspection of its clinical laboratory facilities, equipment, processes, quality control measures, and personnel qualifications—conducted onsite by CAP inspectors.
“The College of American Pathologists is known for the highest standards in laboratory quality,” said Mike Mencer, executive vice president and general manager, Early Phase in a press release. “The CAP Laboratory Accreditation Program provides a clear roadmap for running a high-quality clinical laboratory, with checklists updated annually to ensure we stay current with rapidly evolving advances in medicine, technology, and regulatory compliance as we partner with our customers to develop new medications and treatments. As the latest in our series of investments in facilities, capabilities, and certifications, this accreditation upholds our culture of quality and our commitment to provide customized services to every clinical research program we launch, while adhering to stringent regulatory requirements.”
Operating since 2005 and located in San Antonio, Texas, Worldwide’s CPU is a 200-bed, fit-for-purpose facility. Within this unit, studies are conducted in healthy volunteers, patients, and specialty populations. The CPU is located one hour from Worldwide’s Bioanalytical Center of Excellence, offering an approach that benefits customers through vendor management, consistent standards, technical expertise, and overall efficiencies such as sample transfer and processing.
Worldwide opened the Bioanalytical Center of Excellence in June 2022 in Austin, Texas, to support its Early Phase development and expansion. The 57,000 square foot facility offers about 20 percent more usable space than the previous lab, and is outfitted with modern infrastructure, improved air control, and efficient lab space to flexibly support current and future early phase research demands while enabling optimized workflows to ensure critical customer timelines are met. The expansion also included the addition of large molecule capabilities and services, led by Dr. Tom Zhang, with a 15,000 square foot large molecule lab within the Bioanalytical Center of Excellence.
Worldwide Clinical Trials’ Clinical Pharmacology Unit Earns Accreditation from the College of American Pathologists. (2023, September 14). Business Wire.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.